GHP Investment Advisors Inc. Sells 572 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

GHP Investment Advisors Inc. decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 57.1% during the 4th quarter, HoldingsChannel reports. The fund owned 429 shares of the medical equipment provider’s stock after selling 572 shares during the period. GHP Investment Advisors Inc.’s holdings in Zimmer Biomet were worth $45,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. BLB&B Advisors LLC grew its holdings in shares of Zimmer Biomet by 2.1% during the third quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after purchasing an additional 100 shares during the last quarter. CKW Financial Group boosted its position in Zimmer Biomet by 11.7% during the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock worth $101,000 after buying an additional 100 shares during the period. FWG Holdings LLC grew its holdings in Zimmer Biomet by 2.9% during the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after acquiring an additional 101 shares during the last quarter. Romano Brothers AND Company increased its position in Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after acquiring an additional 102 shares during the period. Finally, Financial Advocates Investment Management raised its stake in shares of Zimmer Biomet by 3.5% during the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after acquiring an additional 103 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ZBH. Barclays decreased their price objective on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Wells Fargo & Company raised their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Raymond James lowered their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $124.70.

Zimmer Biomet Trading Down 1.6 %

NYSE ZBH opened at $101.01 on Friday. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 52 week low of $99.93 and a 52 week high of $133.90. The business has a 50 day moving average price of $107.56 and a 200-day moving average price of $108.16. The company has a market cap of $20.11 billion, a price-to-earnings ratio of 19.20, a P/E/G ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same quarter last year, the firm posted $2.20 earnings per share. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.